Initial installation under the Ministry-led medication decision support program, ahead of phased deployment across Israel's government medical centers

CALGARY, AB, Oct. 20, 2026 /CNW/ -- Seegnal Inc. (TSXV: SEGN) (FSE: 2I1) ("Seegnal" or the "Company"), a developer of innovative healthcare technology focused on mitigating medication risks, is pleased to announce that Seegnal has completed an initial installation within the Israeli Ministry of Health's Government Medical Centers Division, marking a major execution milestone under the Ministry-led Medication Decision Support System ("MDSS") project for government medical centers.

The installation advances a phased program intended to support safer, more personalized medication decisions across Israel's government medical center network. Ness Technologies ("Ness") is serving as the prime contractor for the project, with Seegnal providing its medication decision support technology and related services as a subcontractor.

The Ministry's tender framework provides a pathway for phased deployment across multiple general hospitals, with the potential to extend to additional psychiatric and geriatric centers. The initial installation marks the first operational milestone under that framework. The timing, scope and locations of additional deployments remain subject to Ministry decisions, approved work orders and the completion of applicable implementation milestones.

Seegnal's platform integrates patient-specific clinical information, including current medications, laboratory results, renal function, allergies, age and other relevant risk factors, to deliver context-aware medication guidance at the point of care. The platform is designed to identify clinically significant medication risks while reducing less relevant alerts that can contribute to alert fatigue.

"Completing the initial installation with the Ministry of Health is a significant milestone for Seegnal and reflects our team's continued execution," said Elad Bibi-Aviv, Chief Executive Officer of Seegnal. "This project expands our presence within large, complex healthcare environments and supports the program's next stages. We are proud to work alongside Ness and the Ministry in advancing patient-specific medication intelligence across Israel's government medical center network."

With the initial Ministry installation now complete, Seegnal and its project partners will proceed with the program's next implementation stages. Further deployments remain subject to technical integration, acceptance testing, Ministry work orders and other project requirements. The Company intends to provide updates as additional material milestones are achieved.

About Seegnal

Seegnal Inc. (TSXV: SEGN) (FSE: 2I1) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company's SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing and advance a more personalized standard of patient care. Seegnal's technology is deployed across healthcare settings and is used by approximately 15,000 clinicians in daily practice. For additional Company information, please visit https://www.seegnal.com/ and follow us on LinkedIn.

Forward-Looking Statements

This news release includes certain "forward-looking information" as defined under applicable Canadian securities legislation, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding: the phased implementation of the Ministry of Health medication decision support project; the potential deployment of Seegnal's platform at additional government medical centers; the timing, scope and locations of any future deployments; the completion of applicable technical integration, acceptance testing and implementation milestones; the intended results of the initial installation; the ability of Seegnal's platform to integrate patient-specific clinical information, including current medications, laboratory results, renal function, allergies, age and other relevant risk factors, to deliver context-aware medication guidance at the point of care; and the anticipated clinical and operational benefits of Seegnal's platform. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements of the Company. Such risks and uncertainties include, without limitation: additional deployments may be delayed, reduced in scope or not proceed; required technical integration, acceptance testing, Ministry work orders or other implementation milestones may not be completed on the anticipated timeline or at all; the relationship with Ness as prime contractor may not continue to be beneficial for the Company; and the anticipated clinical and operational benefits of Seegnal's platform may not be realized as expected or at all. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information, which speak only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Seegnal Inc.